Wakeling AE - Search Results

1

Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.

Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK, Hilsenbeck S, Schiff R. Massarweh S, et al. Among authors: wakeling ae. Cancer Res. 2006 Aug 15;66(16):8266-73. doi: 10.1158/0008-5472.CAN-05-4045. Cancer Res. 2006. PMID: 16912207

2

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.

Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R. Shou J, et al. Among authors: wakeling ae. J Natl Cancer Inst. 2004 Jun 16;96(12):926-35. doi: 10.1093/jnci/djh166. J Natl Cancer Inst. 2004. PMID: 15199112

3

Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.

Lu C, Speers C, Zhang Y, Xu X, Hill J, Steinbis E, Celestino J, Shen Q, Kim H, Hilsenbeck S, Mohsin SK, Wakeling A, Osborne CK, Brown PH. Lu C, et al. J Natl Cancer Inst. 2003 Dec 17;95(24):1825-33. doi: 10.1093/jnci/djg117. J Natl Cancer Inst. 2003. PMID: 14679152

4

Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action.

Osborne CK, Wakeling A, Nicholson RI. Osborne CK, et al. Br J Cancer. 2004 Mar;90 Suppl 1(Suppl 1):S2-6. doi: 10.1038/sj.bjc.6601629. Br J Cancer. 2004. PMID: 15094757 Free PMC article. Review.

5

Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.

Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, Manning DL, Nicholson RI. Osborne CK, et al. Among authors: wakeling ae. J Natl Cancer Inst. 1995 May 17;87(10):746-50. doi: 10.1093/jnci/87.10.746. J Natl Cancer Inst. 1995. PMID: 7563152

6

ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen.

Howell A, Osborne CK, Morris C, Wakeling AE. Howell A, et al. Among authors: wakeling ae. Cancer. 2000 Aug 15;89(4):817-25. doi: 10.1002/1097-0142(20000815)89:4<817::aid-cncr14>3.0.co;2-6. Cancer. 2000. PMID: 10951345

7

The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth.

Osborne CK, Jarman M, McCague R, Coronado EB, Hilsenbeck SG, Wakeling AE. Osborne CK, et al. Among authors: wakeling ae. Cancer Chemother Pharmacol. 1994;34(2):89-95. doi: 10.1007/BF00685924. Cancer Chemother Pharmacol. 1994. PMID: 8194171

8

Pure antiestrogens. The most important advance in the endocrine therapy of breast cancer since 1896.

Nicholson RI, Gee JM, Bryant S, Francis AB, McClelland RA, Knowlden J, Wakeling AE, Osborne CK. Nicholson RI, et al. Among authors: wakeling ae. Ann N Y Acad Sci. 1996 Apr 30;784:325-35. doi: 10.1111/j.1749-6632.1996.tb16247.x. Ann N Y Acad Sci. 1996. PMID: 8651581 Review. No abstract available.

9

MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780.

Brünner N, Frandsen TL, Holst-Hansen C, Bei M, Thompson EW, Wakeling AE, Lippman ME, Clarke R. Brünner N, et al. Among authors: wakeling ae. Cancer Res. 1993 Jul 15;53(14):3229-32. Cancer Res. 1993. PMID: 8324732

10

Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes.

McClelland RA, Manning DL, Gee JM, Anderson E, Clarke R, Howell A, Dowsett M, Robertson JF, Blamey RW, Wakeling AE, Nicholson RI. McClelland RA, et al. Among authors: wakeling ae. Breast Cancer Res Treat. 1996;41(1):31-41. doi: 10.1007/BF01807034. Breast Cancer Res Treat. 1996. PMID: 8932874

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

126 results

Search Page

Filters